Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG406 in Locally Advanced/Metastatic Solid Tumors
NCT06979674Phase 1Recruiting
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ESG406 in solid tumor, sponsored by Shanghai Escugen Biotechnology Co., Ltd. Primary endpoint: Treatment Emergent Adverse Events. Started Jun 2025; status: recruiting.
02
Drugs
ESG406
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06979674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979674.